Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Oct 31, 2024 (2 years ago)

Xelstrym (dextroamphetamine)

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Defective Delivery System: The product does not meet predetermined specifications for Coldflow (adhesive).

Cause type: Packaging defect

Failed child-resistant closures, leaks, cracked containers, or a defective delivery device. Packaging failures risk accidental exposure (especially to children) or product contamination. All packaging defect recalls.

What was recalled

Xelstrym (dextroamphetamine) transdermal system, 13.5 mg dextroamphetamine/9 hours, 30 individually sealed transdermal patches, inside a foil-sealed polypropylene tray, packed in a paper carton/box, MANUFACTURED BY NOVEN PHARMACEUTICALS, INC., Miami, FL 33186 United Sates, NDC 68968-0215-3

Affected NDC 68968-0215-03

Compare with the code on your package — it is the most precise check available.

Drug: Dextroamphetamine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Xelstrym
Dextroamphetamine
NDC 68968-0215
13.5 mg/1 Patch, Extended Release
Transdermal
Noven Therapeutics, LLC Rx · CII
Recalling firm
Noven Pharmaceuticals Inc
NDC code
68968-0215-3
Origin
FL, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0055-2025 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other Dextroamphetamine recalls

See all
Class II · Moderate risk

Dextroamphetamine Saccharate

Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules.

Ongoing Labeling / mix-up Lannett Company Inc. D-0660-2026

Other recalls by Noven Pharmaceuticals Inc

All 2024 recalls